Abstract
Evaluation of 68Ga-labeled TPP-1: A Targeted PD-L1 Probe for PET Imaging of Colorectal Cancer
Highlights
Colorectal cancer is a common clinical malignancy of the digestive system
For Positron emission tomography (PET) imaging studies, 3.7MBq 68Ga-TPP-1 was injected into the tail veins of a mouse bearing colorectal cancer (N=3), the blocking group was pre-injected with the 20-fold molar excess of unlabeled TPP-1 one hour in advance
PET imaging showed that the tumor was of highly uptake of 68Ga-TPP-1, and the physiological uptake in the kidney and bladder were detected
Summary
Colorectal cancer is a common clinical malignancy of the digestive system. In recent years, with the improvement of living standards and changes in dietary habits, the incidence and death rate of colorectal cancer has been on the rise [1]. Effective treatments for colorectal cancer include surgery, chemotherapy and radiotherapy, but most lesions have already metastasized at the time point of being detected, resulting in a high death rate. Immuno-blocking therapy (IBT) targeting the PD-1/PD-L1 pathway has shown impressive clinical results, only a small number of patients have been benefited [4]. Positron emission tomography (PET) imaging with radiolabeled anti-PD-L1 antibodies has shown vital advantages over immunohistochemistry in evaluating PD-L1 expression [5]. PD-1/PD-L1-targeted nuclear imaging enables the quantification of primary and metastatic lesions as well as systemic PD-1/PD-L1 expression by replacing invasive tests such as puncture, providing a more accurate screening method for patients on PD-1/PD-L1 immunotherapy. The tracer 68Ga-TPP-1 showed good application in PD-L1 expression imaging in MC38 xenograft tumors and had promising applications in guiding immunotherapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
